Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied. Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301 000), and a concurrent group of beneficiaries without CKD (n = 15 772 039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest. Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8% of CKD patients in 1992 and to 7.5% in 2004. Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.
Introduction
Anaemia is a classic consequence of reduced renal function, and its prevalence is almost universal by the time chronic kidney disease (CKD) progresses to end-stage renal disease (ESRD) (1) (2) . The introduction of erythropoiesis stimulating agents (ESAs) has improved the quality of life for CKD patients, including those on dialysis (3) (4) (5) (6) . We recently showed reduced transfusion frequency in a large cohort of dialysis patients studied between 1992 and 2004 (7) . Surprisingly, little is known regarding the effect of ESA use on the frequency of blood transfusions in CKD patients who are not on dialysis.
Therefore, we compared the transfusion experience of a large cohort of Medicare beneficiaries with non-dialysisdependent CKD to the experience of beneficiaries without CKD. We also compared ESA use and parenteral iron use in beneficiaries with and without CKD. We tested the hypothesis that ESA use is responsible for most of the observed reduction in transfusion frequency in elderly anaemic CKD patients.
Subjects and methods

Study cohorts
We studied 301 000 general Medicare beneficiaries who entered the Part A and Part B programmes from 1992 through 2004. Medicare Part A reimburses health care providers for services to Medicare beneficiaries during hospitalizations, and it covers facility costs. Medicare Part B covers services provided by hospital outpatient departments, rural health clinics, dialysis facilities, outpatient rehabilitation services and community mental health centres. Most citizens or permanent residents of the United States aged 65 years or older are eligible for Part A coverage if they are eligible for Social Security benefits. Before age 65 years, Medicare coverage is available only to people with disabilities or with ESRD. Anyone eligible for Medicare Part A can enrol in Part B by paying a monthly premium.
Included patients entered the Medicare programme before 1 January of each year, were aged 65 years or older at the beginning of each year, survived and remained in the programme through 31 December of each year and had non-dialysis-dependent CKD diagnosed in each year (entry year). Henceforth in this report, 'CKD' means 'non-dialysis-dependent CKD'. Patients enrolled in health maintenance organizations, with Medicare as secondary payer, diagnosed with ESRD, or not residing in the 50 US states, the District of Columbia, Puerto Rico or the Territories during each year were excluded. Patients with evidence of cancer or blood dyscrasias during the 12-month entry period for each year were also excluded, as these patients can be hyporesponsive to ESA therapy and may require multiple transfusions not directly related to anaemia of CKD. The relevant exclusions with International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) codes are shown in Table 1 . Patients who did not survive the entry period were also excluded.
CKD and comorbid conditions were defined during the 12-month entry period. Conditions were defined by the presence of one inpatient Part A claim or two outpatient Part B or one Part A and one Part B claims. ICD-9-CM codes used to define CKD and relevant comorbid conditions used to describe the cohort are listed in Table 1 . Based on claim source (inpatient or outpatient/Part B claims), CKD and comorbid conditions were further classified as follows: inpatient claim source if the inpatient claim occurred before the second Part B or outpatient claim, or in the absence of a Part B or outpatient claim; outpatient claim source if the second outpatient or Part B claim occurred before an inpatient claim or in the absence of an inpatient claim. Transfusions billed by outpatient facilities and those administered during inpatient hospital stays were obtained from Part A files using code files for both whole and packed cell transfusions. Those obtained from Part B files included whole and packed red blood cell transfusions, regardless of whether these were leukocyte reduced, irradiated or deglycerolized. ESA use was defined during the entry period by Healthcare Common Procedure Coding System (HCPCS) codes. Anaemia was defined the same way that CKD was defined, using ICD-9-CM codes 280.xx-285.xx, encompassing all haemolytic, non-haemolytic and bone-marrow-failure-related anaemia (see Table 1 ).
A non-CKD cohort including 15 772 039 patients was also studied from 1992 through 2004, applying similar methodology and exclusions.
Analysis
Categorical variables are presented as percentages. Patients were followed from 1 January of each year to 31 December of the next year for blood transfusions and were censored at death, ESRD diagnosis and payer status change. Raw transfusion rates were calculated by the total number of transfusions over total follow-up time. Adjusted transfusion rates were calculated by the Poisson model. Seven models were fitted by adjusting for the following covariates:
Model 1: age, sex, race. Model 2: age, sex, race and ESA use in the entry year. Model 3: age, sex, race and ESA use and hospital stays in the entry year. Model 4: age, sex, race and comorbid conditions in the entry year. Model 5: age, sex, race and ESA use, hospital stays and comorbid conditions in the entry year. Model 6: age, sex, race and ESA use, hospital stays and CKD and comorbid condition claim source (inpatient or outpatient) in the entry year. Adjustment for some of these comorbid conditions was done due to their potential to cause anaemia directly (e.g. gastrointestinal disorders) or to be associated with anaemia of CKD. The 1992 cohort was used as the reference group for these six models. An additional model, model 7, was similar to model 6 but used 2004 as the reference year. As the adjusted models gave comparable results, only results from model 7 are presented.
Results
General Characteristics of CKD and Non-CKD cohorts
We studied 301 000 Medicare patients with CKD, 1992-2004. The number of patients rose steadily, from 14 057 in 1992 to 42 225 in 2004 (Table 2) , and the increase was uniform across all age groups (ages 65-74, 75-84 and ≥85 years). In 2004, women constituted 55.2% of the CKD cohort and white patients 82.6%. Approximately a third of CKD patients were hospitalized at least once for an average of 1-7 days during the observation period. Interestingly, the proportion of CKD patients hospitalized for 8 or more days fell from 35.8% in 1992 to 27.2% in 2004. Claims related to ASHD were present for approximately half the CKD cohort during the observation period, claims related to CHF for 40% and claims related to CVA/TIA for 20%. The proportions of patients with these three conditions changed little from 1992 to 2004. The prevalence of diabetes, PVD, hypertension and COPD rose steadily over the study period. In 2004, the reported diabetes prevalence was 48.4% and the hypertension prevalence 89.0%. The anaemia prevalence increased from 31.1% in 1992 to 44.0% in 2004, paralleled by a steady increase in ESA use by almost 10-fold from 0.8% in 1992 to 7.5% in 2004. We also found a steady, though small, increase in parenteral iron use in the entry year. In 1992, only 0.1% of CKD patients received parenteral iron, rising to 1.0% in 2004.
The non-CKD cohort included 15 772 039 Medicare patients (Table 3) . In this cohort, 13.2% were aged older than 85 years compared with 20.6% in the CKD cohort. The proportion of African Americans was also lower, 7.3% compared with 12.9% in the CKD cohort. A substantially lower proportion (17.5%) than in the CKD cohort were hospitalized in the entry period, and the comorbidity burden, especially ASHD, CHF, CVA/TIA, diabetes and hypertension was lower. The anaemia prevalence was also much lower, at 9.0% versus 39.5% in the CKD cohort. ESA and iron use was negligible in the non-CKD cohort. (Table 4) .
ESA use and transfusions
In 1992, 0.8% of CKD patients received ESAs, rising to 7.5% in 2004 ( 
Discussion
Our data demonstrate that transfusion rates for non-dialysisdependent CKD patients are 4-to 5-fold higher than rates for non-CKD patients. Transfusion rates declined markedly between 1992 and 2004, with the largest decline for anaemic CKD patients who received ESAs. Paralleling the decrease in blood transfusions, increases in the frequency of ESA use and, to a lesser extent, parenteral iron use were noted. CKD patients who received transfusions were more likely to receive ESAs, reflecting a high comorbidity burden. While blood transfusion use has declined, transfusions remain frequent. Undoubtedly, ESA use accounts for a proportion of the reduction; however, transfusion avoidance during the study period, as suggested by the decline in transfusions in the non-CKD population, may play a role. of dialysis patients we previously reported on, covering the same study period (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) , reveals that transfusion rates were 2.7-fold higher for haemodialysis than for non-dialysis-dependent CKD patients in 1992 and 2.1-fold higher in 2005 (7) . Red blood cell transfusions are not without risks, including transfusion reactions, transmission of infectious agents and iron overload (8) . Before the widespread adoption of ESA therapy, 41% of dialysis patients were estimated to show evidence of iron overload incurred from multiple blood transfusions; this era has fortunately passed (9) . Other concerns include associated costs and the potential adverse effect of blood transfusions on the development of allo-antibodies, which in turn can prolong time on the kidney transplant waiting list and possibly jeopardize the kidney transplant outcome (10) . Continued efforts to minimize transfusion use, in accordance with the US Food and Drug Administration guidelines, will likely minimize the risks associated with transfusions. Identifying correctable causes of anaemia, using ESAs thoughtfully, providing adequate iron stores and improved understanding of reasons for blood transfusion use may help reduce that use.
Our study is inherently limited by its retrospective design. Furthermore, we had no information on the numbers of or reasons for transfusions given to individual patients, as indications for giving transfusions are not available in claim data. Importantly, some non-anaemic CKD patients not receiving ESAs received transfusions. This most likely represents transfusions given due to trauma, surgical procedure or gastrointestinal bleeding. It may also reflect a general feeling in the medical community that sick patients, particularly those with heart disease, benefit from higher haemoglobin levels, despite lack of evidence to support such practice (11) . This latter possibility needs to be substantiated. Also relevant is the unavailability of haemoglobin levels at which transfusions took place; this limits the ability to draw conclusions regarding whether the haemoglobin threshold at which clinicians transfuse CKD patients changed during this study period.
Our study used administrative claim data to define blood transfusion occurrences. The accuracy of billing data for identifying blood transfusions is unknown, but is likely similar to the accuracy for other procedures, given that reimbursement is tied to accurate claim submission and erroneous claims are considered fraud. Finally, the temporal trends in blood transfusion use may not be causally related to increasing ESA use, but to other factors, such as a decreased role of blood transfusions in medical practice, as suggested by the decline in transfusion rates for nonanaemic non-CKD patients between 1992 and 2004. The former possibility, however, remains more likely.
In conclusion, these data indicate an encouraging decline in transfusion rates for both CKD and non-CKD Medicare patients, and ESA use is largely responsible for the observed reduction in transfusion use in the setting of CKD. More research is needed to better identify potentially avoidable transfusions, as understanding the reasons for transfusion use may lead to thoughtful avoidance of those that are not absolutely necessary.
